Literature DB >> 18214046

Expression of integrin-linked kinase is not a useful prognostic marker in resected hepatocellular cancer.

Pongphob Intaraprasong1, Kiran Assi, David A Owen, David G Huntsman, Stephen W Chung, Charles H Scudamore, Eric M Yoshida, Baljinder Salh.   

Abstract

BACKGROUND: Hepatocellular cancer (HCC) is one of the most common malignancies worldwide, and is known to be associated with a poor prognosis. Unfortunately there are no available reliable markers of prognosis. The aim of this study was to determine whether integrin-linked kinase (ILK) expression correlates with post-resection survival from HCC. PATIENTS AND METHODS: A tissue microarray was constructed using HCC samples, and immunohistochemical analysis for ILK was then carried out and scored by three independent observers. Clinical chart review was performed to determine survival parameters.
RESULTS: Of the 52 cases of HCC, 22 cases were associated with hepatitis B (HBV), 18 with hepatitis C (HCV), 2 with HBV and HCV co-infection; 81% of all patients were male and 19% female. Western immunoblotting showed a highly significant correlation between levels of expression of ILK and ser473-PKBphosphorylation, both in control and tumor sections (Spearman rank correlation, r=0.8155, p=0.0004), however, there was no direct correlation between the levels of expression of ILK with patient survival (log-rank test, p= 0.864).
CONCLUSION: ILK expression does not appear to have a role in predicting outcome in patients with resected HCC.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18214046

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  4 in total

1.  ILK and PRDX1 are prognostic markers in squamous cell/adenosquamous carcinomas and adenocarcinoma of gallbladder.

Authors:  Jinghe Li; Zhu-Lin Yang; Xuebao Ren; Qiong Zou; Yuan Yuan; Lufeng Liang; Meigui Chen; Senlin Chen
Journal:  Tumour Biol       Date:  2012-10-13

Review 2.  Integrin Linked Kinase (ILK) and its Role in Liver Pathobiology.

Authors:  Nicole Martucci; George K Michalopoulos; Wendy M Mars
Journal:  Gene Expr       Date:  2021-01-22

3.  Integrin-linked kinase overexpression and its oncogenic role in promoting tumorigenicity of hepatocellular carcinoma.

Authors:  Jenny Chan; Frankie Chi Fat Ko; Yin-Shan Yeung; Irene Oi-Lin Ng; Judy Wai Ping Yam
Journal:  PLoS One       Date:  2011-02-09       Impact factor: 3.240

4.  QLT0267, a small molecule inhibitor targeting integrin-linked kinase (ILK), and docetaxel can combine to produce synergistic interactions linked to enhanced cytotoxicity, reductions in P-AKT levels, altered F-actin architecture and improved treatment outcomes in an orthotopic breast cancer model.

Authors:  Jessica Kalra; Corinna Warburton; Karen Fang; Lincoln Edwards; Tim Daynard; Dawn Waterhouse; Wieslawa Dragowska; Brent W Sutherland; Shoukat Dedhar; Karen Gelmon; Marcel Bally
Journal:  Breast Cancer Res       Date:  2009-05-01       Impact factor: 6.466

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.